BUZZ-Guggenheim initiates coverage on Crescent Biopharma with 'buy'

Reuters01-21
BUZZ-Guggenheim initiates coverage on Crescent Biopharma with 'buy'

** Guggenheim starts coverage on drugmaker Crescent Biopharma CBIO.O with "buy"; sets PT at $35

** Says CBIO has a compelling investment thesis as it awaits long-term data for its experimental lung cancer treatment, CR-001, in Q1 2027

** Says this will provide a clear comparable to Summit's SMMT.O ivonescimab, which belongs to a similar class of drugs

** CBIO's proprietary antibody-drug conjugate $(ADC)$ pipeline, known as "guided-missile" cancer drugs, could generate independent value as monotherapy and be synergistic with CR-001 in earlier solid tumor treatment settings - Brokerage

** "We see CBIO as set up to be awarded significant value both from what the company is replicating and what the company is pioneering" - Brokerage

** As of last close, CBIO stock down 52.37% in the past 12 months

(Reporting by Gnaneshwar Rajan in Bengaluru)

((Gnaneshwar.Rajan@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment